StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2135.HK$0.12+0.00%
Fair $0.12+0.0%

2135.HK

Raily Aesthetic Medicine International Holdings Limited

Healthcare / Medical Care FacilitiesHKSE

$0.12

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.12Fund rank 28/100 · Data gapFallback financials|
SA 28/D
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-10.0M · quality 49.7/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 21/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

28/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: yahooPeriods: 5Warnings: 1yahoo: 5
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is 1.7%, below the 5% threshold
Thesis & Journal · 2135.HKLocal privado en este navegador · Raily Aesthetic Medicine International Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$68M

P/E

N/A

•

EV/EBITDA

2.7x

↓

ROE

1.7%

↑

Gross Margin

41.0%

↓

Debt/Equity

0.55

↑
52-Week Range$0
$0$0

TradingView lightweight chart

2135.HK price, volumen y niveles de valoración

Último $0.123Periodo -93.5%
Fair value: $0.122

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

+0.1%

FCF CAGR

—

FCF margin

13.0%

FCF / Net income

13.14x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $189.4M · net income $1.9M · FCF $24.6M

2021-FY → 2025-FY

Gross margin

41.0%+4.0% pts

Operating margin

3.5%+13.7% pts

Net margin

1.0%+10.4% pts

FCF margin

13.0%+22.7% pts
MetricTTM
2025
2024
2023
2022
2021
Income Statement
Revenue$189.4M$189.4M$199.3M$189.4M$164.5M$188.4M
Net Income$1.9M$1.9M$-59.2M$-32.5M$-15.9M$-17.7M
EBITDA$25.3M$25.3M$-34.3M$-6.0M$3.9M$-6.0M
EPS——-0.11-0.34-0.03-0.04
Gross Margin41.0%41.0%35.8%37.8%40.6%37.0%
Operating Margin3.5%3.5%-9.4%-11.9%-12.3%-10.2%
Net Margin1.0%1.0%-29.7%-17.1%-9.7%-9.4%
Balance Sheet
Debt/Equity0.550.550.540.370.290.38
Current Ratio0.770.77————
Cash Flow
Free Cash Flow$24.6M$24.6M$-38.6M$-10.0M$-21.1M$-18.2M
Returns
ROE1.7%1.7%-56.9%-23.5%-9.6%-9.9%
Valuation
EV/EBITDA2.742.74——89.81—
P/B0.630.630.520.292.293.40
Growth & Yield
Revenue Growth-5.0%-5.0%5.3%15.1%——
EPS Growth——67.1%-919.7%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.9%

Total return

+7.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.11 → n/d

Residual

+7.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+7.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.